title: Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial".
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Benjamin M
authors.initials: BM
authors.lastname: Scirica
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Eugene
authors.initials: E
authors.lastname: Braunwald
authors.affiliation: Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
authors.forename: Itamar
authors.initials: I
authors.lastname: Raz
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Cavender
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: David A
authors.initials: DA
authors.lastname: Morrow
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston, MA.
authors.forename: Petr
authors.initials: P
authors.lastname: Jarolim
authors.affiliation: Cardiovascular Division, Women's College Hospital and Toronto General Hospital, University of Toronto, Toronto, Canada.
authors.forename: Jacob A
authors.initials: JA
authors.lastname: Udell
authors.affiliation: Diabetes Unit, Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
authors.forename: Ofri
authors.initials: O
authors.lastname: Mosenzon
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: KyungAh
authors.initials: K
authors.lastname: Im
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Amarachi A
authors.initials: AA
authors.lastname: Umez-Eronini
authors.affiliation: AstraZeneca Research and Development, Wilmington, DE.
authors.forename: Pia S
authors.initials: PS
authors.lastname: Pollack
authors.affiliation: AstraZeneca Research and Development, Wilmington, DE.
authors.forename: Boaz
authors.initials: B
authors.lastname: Hirshberg
authors.affiliation: Bristol-Myers Squibb, Princeton, NJ.
authors.forename: Robert
authors.initials: R
authors.lastname: Frederich
authors.affiliation: Cardiovascular Research Institute, Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport School of Medicine Technion-IIT, Haifa, Israel.
authors.forename: Basil S
authors.initials: BS
authors.lastname: Lewis
authors.affiliation: Cardiovascular Medicine, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Jaime
authors.initials: J
authors.lastname: Davidson
authors.affiliation: Département Hospitalo-Universitaire FIRE, INSERM U-1148, Université Paris-Diderot, Hôpital Bichat, AP-HP, Paris, France, NHLI Imperial College, ICMS, Royal Brompton Hospital, London, UK.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Steg
authors.affiliation: TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.
authors.forename: Deepak L
authors.initials: DL
authors.lastname: Bhatt
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D004151:Dipeptides / Q000009:adverse effects*; D005260:Female; D006333:Heart Failure / Q000139:chemically induced* / Q000150:complications*; D006801:Humans; D008297:Male
chemical_list: D004151:Dipeptides; D000218:Adamantane